OS Benefit from TTFields with Gemcitabine/Nab-paclitaxel for Patients with Unresectable Locally Advanced Pancreatic Adenocarcinoma By Ogkologos - August 4, 2025 726 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the PANOVA-3 study Source RELATED ARTICLESMORE FROM AUTHOR Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with BRAF V600E-mutated mCRC FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors MOST POPULAR When You Have to Make Decisions for a Loved One With... November 9, 2020 Investment Needed to Bring Down Pancreatic Cancer Death Rates in Europe.... February 22, 2021 Telehealth-Based Cancer Care Surged during COVID. Will It Continue? March 9, 2022 Discovering the BRCA2 gene – 25 years on January 14, 2021 Load more HOT NEWS Oligoprogression in Metastatic NSCLC Could Be Effectively Treated with SBRT Plus... Avapritinib Approved to Treat GIST with a Rare Gene Alteration FDA Recognises OncoKB Database of Molecular Tumour Marker Information FDA Approves Pembrolizumab with Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube,...
